Class / Patent application number | Description | Number of patent applications / Date published |
514576000 | Benzene ring containing | 38 |
20080275125 | Combination Composition - A combination pharmaceutical composition for the treatment of pain including about 125 mg to about 150 mg ibuprofen and about 475 mg to about 500 mg paracetamol. | 11-06-2008 |
20080293816 | Use of 2,5-Dihydroxybenzenesulphonic Acid in the Production of Medicaments for the Treatment of Angiodependent Diseases Such as Cancer and Psoriasis - The invention relates to the use of 2,5-dihydroxybenzenesulfonic acid in the production of medicaments for the treatment of angiodependent diseases. More specifically, the invention relates to the use of the aforesaid compound and, in particular, the calcium and potassium salts thereof, for the treatment of two angiodependent diseases, which present a reduction in the apoptosis, namely cancer and psoriasis. The invention also discloses the antiproliferative, antimigratory, antiangiogenic and proapoptotic capacity of said family of compounds in non-quiescent cells. In addition, the invention details the potentiating effect of said compounds on known cytostatic medicines in the treatment of tumours and, specifically, on gliomas. The invention further relates to the therapeutic efficacy of said compounds, based on the combined antiproliferative, antiangiogenic and proapoptotic capacities thereof, in the treatment of chronic psoriatic plaques. | 11-27-2008 |
20090018200 | COMPOSITION CONTAINING A PHENANTHRENOL - Novel uses of phenanthrenol compounds for improving the appearance and/or texture of the skin. | 01-15-2009 |
20090082454 | DEUTERIUM-ENRICHED DISUFENTON - The present application describes deuterium-enriched disufenton, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 03-26-2009 |
20090088477 | Compounds and methods for leukotriene biosynthesis inhibition - This invention provides novel salt and crystalline forms thereof of (−)4-(4-fluorophenyl)-7-[({5-[1-hydroxy-1-(trifluoromethyl)propyl]-1,3,4-oxadiazol-2-yl}amino)-methyl]-2H-chromen-2-one. The compounds are 5-LO inhibitors and are useful for treatment of conditions such as asthma, allergic rhinitis, COPD, and atherosclerosis. | 04-02-2009 |
20090176885 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS - Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, polycystic ovary syndrome, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed. Formula (I) wherein n is 1 or 2; m is 0, 1, 2, 3, or 4; q is 0 or 1; t is 0 or 1; R | 07-09-2009 |
20090264532 | PRESERVATIVES BASED ON CARBOXYLIC ANHYDRIDES - Carboxylic anhydrides are highly suitable as additive for industrial materials, cosmetics, pharmaceutics and foodstuffs, in particular beverages, for protecting them against attack and/or destruction by microorganisms. | 10-22-2009 |
20100041759 | MULTI-PHASE RELEASE POTASSIUM GUAIACOLSULFONATE COMPOSITIONS - Formulations have been developed administering a guaiacolsulfonate salt, preferably potassium salt, in multi-phases. In a preferred embodiment, the formulation contains potassium guaiacolsulfonate in an immediate release (“IR”) form and a sustained or delayed release (“DR”) form and/or pulsed release (“PR”) form. In another embodiment, the potassium guaiacolsulfonate is released in a gradient, decreasing the side effects associated with rapidly elevated blood levels. In another embodiment, the drug is bound to an ion-exchange resin, which can be suspended in a liquid or incorporated into a matrix for delayed, sustained and/or pulsed release. Dosage unit forms may be tablets, gels, liquids, capsules, beads, microparticles, films or lozenges. Multi-phase delivery can also be achieved through the use of a kit that provides for dosage escalation. The formulations are useful in the treatment of one or more symptoms of coughs, colds, sinusitis and other respiratory illnesses. The formulations are also useful in the treatment or relief of fibromyalgia, pain, and Irritable Bowel Syndrome. | 02-18-2010 |
20100087541 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS - Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed. | 04-08-2010 |
20100152296 | PHOTOPOLYMERIZATION MATERIAL FOR GUMS ISOLATION - The main goal of the present invention is the development of a polymerizable material for isolation and protection of the gums and generally the soft tissues of the oral cavity. For better protection during various procedures of the dental surfaces. The composition of the material can contain many other substances that strengthen its qualities and protective action. Such substances can be various substances that have antioxidative, sedative, anti-inflammatory, analgesic, anti-irritant action etc. | 06-17-2010 |
20100227928 | NON-STEROIDAL ANTI-INFLAMMATORY OPHTHALMIC COMPOSITIONS - The disclosure provides compositions and systems for topical ophthalmic application, which include an aqueous mixture of bromfenac and flowable mucoadhesive polymer, for treating inflammation and inflammatory conditions of the eye. | 09-09-2010 |
20110124732 | DEUTERIUM-ENRICHED DISUFENTON - The present application describes deuterium-enriched disufenton, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 05-26-2011 |
20110196040 | Skin Penetration Enhancing Systems for Polar Drugs - The invention relates to pharmaceutical compositions and related methods for the topical administration of polar drugs. In a particular embodiment, the invention relates to a pharmaceutical composition comprising an active pharmaceutical agent that is a polar drug, such as potassium 2,5-dihydroxybenzenesulfonate, at least one occlusive agent, and at least one stabilizer. | 08-11-2011 |
20110230562 | MELANINS SYNTHESIZED CHEMICALLY OR VIA ENZYME CATALYSIS - The present invention provides an enzymatic and a chemical synthesis of melanins and novel melanins. | 09-22-2011 |
20120046364 | Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use - The present invention relates to sulfonic acid containing compounds of formula IB, in which G, R | 02-23-2012 |
20120136061 | LYCOPENE AND RESVERATROL COMPOSITIONS FOR NK CELL ACTIVATION RESULTING IN ANTI-NEOPLASTIC EFFECT - A carotenoid and a terpenoid in therapeutically-effective amounts is disclosed such that, upon ingestion in one preparation, or in two separated preparations, simultaneous or sequentially, and upon metabolism, the activity of natural killer (NK) cells is elevated. Specifically, the composition comprises lycopene and resveratrol in the range of 1:10 to 10:1 by molar; more preferably 1:1 to 3:1 by molar, and most preferably at 3:1. Alternatively, the preferred ratio may be expressed as 1:4 to 25:1 by weight; more preferably 2½:1 to 7½:1 by weight, and most preferably at 7½:1. The composition may be formulated for oral intake as a pharmaceutical, dietary supplement or food product and provided in therapeutically effective amounts to a mammal, preferably in a dosage of about 3.5 mg per day per 20 g of a mammalian body mass in a ratio of 2½:1 by weight, which can be translated to about 400 mg to 1000 mg per day for a typical human in need of elevating NK cell activity. Preferably, the therapeutically-effective aspect of the composition includes its metabolically-producing agents, prodrugs, metabolites or intermediate compounds useful in triggering NK cells into cytotoxic or cytolytic response. | 05-31-2012 |
20120142780 | USE OF 2,5-DIHYDROXYBENZENESULFONIC ACID IN THE MANUFACTURING OF MEDICINES, APPLICABLE TO THE TREATMENT OF ANGIODEPENDENT DISEASES - The invention relates to the use of 2,5-dihydroxybenzenesulfonic acid in the production of medicaments for the treatment of angiodependent diseases. More specifically, the invention relates to the use of the aforesaid compound and, in particular, the calcium and potassium salts thereof, for the treatment of two angiodependent diseases, which present a reduction in the apoptosis, namely cancer and psoriasis. The invention also discloses the antiproliferative, antimigratory, antiangiogenic and proapoptotic capacity of said family of compounds in non-quiescent cells. In addition, the invention details the potentiating effect of said compounds on known cytostatic medicines in the treatment of tumours and, specifically, on gliomas. The invention further relates to the therapeutic efficacy of said compounds, based on the combined antiproliferative, antiangiogenic and proapaptotic capacities thereof, in the treatment of chronic psoriatic plaques. | 06-07-2012 |
20120232153 | ACIDIC BIOFILM REMEDIATION - Methods and compositions for biofilm remediation are disclosed. Biofilm is reduced and removed from soiled surfaces by providing to a surface in need an effective amount of a composition comprising a biocidal surfactant and at least one organic solvent. According to the invention, the biofilm remediation compositions reduce and remove biofilm formation by administering a one-step cleaner and disinfectant. The biofilm remediation compositions are stable and effective in concentrated and diluted ready-to-use formulations comprising an anionic sulfated or sulfonated surfactant that is not an organocarboxylic acid, a sparingly soluble organic solvent and optionally a soluble organic solvent. | 09-13-2012 |
20120232154 | PRESERVATIVES BASED ON CARBOXYLIC ANHYDRIDES - Carboxylic anhydrides are highly suitable as additive for industrial materials, cosmetics, pharmaceutics and foodstuffs, in particular beverages, for protecting them against attack and/or destruction by microorganisms. | 09-13-2012 |
20130041037 | THERAPEUTIC APPLICATIONS OF FATTY ACID AMIDE HYDROLASE INHIBITORS - Fatty acid amide hydrolase (FAAH) is an enzyme responsible for the degradation of oleamide (an endogenous sleep-inducing lipid) and anandamide (an endogenous ligand for cannabinoid receptors). Disclosed herein are potent inhibitors of FAAH and methods for their use for treating a variety of disorder, including hypertension and cardiac hypertrophy. | 02-14-2013 |
20130203851 | Use of 2,5-Dihydroxybenzenesulfonic Acid in the Manufacturing of Medicines, Applicable to the Treatment of Angiodependent Diseases - Provided is the use of 2,5-dihydroxybenzenesulfonic acid in the production of medicaments for the treatment of angiodependent diseases. More specifically, described is the use of the aforesaid compound and, in particular, the calcium and potassium salts thereof, for the treatment of two angiodependent diseases, which present a reduction in the apoptosis, namely cancer and psoriasis. Also described is the antiproliferative, antimigratory, antiangiogenic and proapoptotic capacity of said family of compounds in non-quiescent cells. In addition, described is the potentiating effect of said compounds on known cytostatic medicines in the treatment of tumours and, specifically, on gliomas. Additionally, the therapeutic efficacy of said compounds, based on the combined anti proliferative, antiangiogenic and proapaptotic capacities thereof, in the treatment of chronic psoriatic plaques is provided. | 08-08-2013 |
20140135400 | NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR - The present invention provides for novel compounds of Formula (I) and pharmaceutically acceptable salts and co-crystals thereof which have glucagon receptor antagonist or inverse agonist activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance and hyperglycemia. The present invention also provides for processes of making the compounds of Formula I, including salts and co-crystals thereof, and pharmaceutical compositions comprising the same. | 05-15-2014 |
20140187638 | PHENYLBUTYRATE IN RECTAL FORM FOR THE TREATMENT OF A MOTOR NEURON DISEASE OR A METABOLIC DISEASE - The present invention relates to rectal administration of phenylbutyrate for treating a motor neuron disease, such as, for example, spinal muscular atrophy or a metabolic disease such as, for example, an urea cycle disorder, related methods and compositions. | 07-03-2014 |
20150366827 | COMPOSITIONS AND METHODS FOR MIXING AND APPLYING MIXED OXIDANT COMPOSITIONS FOR DAIRY ANIMAL TREATMENT - A method for mixing dairy animal teat dip from water and additives. The method includes a mixing manifold into which the water and additives are fed and mixed in a controlled manner. Mixed teat dip is automatically quality tested and monitored to provide data for controlling quantities of water and additives being fed to the manifold. | 12-24-2015 |
20150377911 | BIOMARKERS FOR CHAGAS DISEASE RELATED CARDIOMYOPATHY - Certain embodiments include methods for assessing a subject having a trypanosome infection for the presence or absence of indications of cardiomyopathy. | 12-31-2015 |
20160009639 | NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR | 01-14-2016 |
20160030345 | Core Compositions - The present invention is directed to a process for adsorbing an active pharmaceutical ingredient onto a substrate, comprising the steps of (a) adding and mixing an inert adsorbent to a non-solid form comprising the active pharmaceutical ingredient, thereby forming a mixture; and (b) drying the mixture to form a solid crumbly material. | 02-04-2016 |
20160058718 | FORMULATION AND METHOD OF TREATING CHRONIC WOUNDS AND PREVENTING BACTERIAL INFECTIONS - Inventive subject matter disclosed herein includes a method for treating a chronic wound, and methods for treating bacterial infections. The method for treating a chronic wound includes mechanically debriding a chronic wound, and applying a formulation to the wound for 5 to 60 seconds, the formulation including: phenolsulfonic acid—37% by weight; guaiacolsulfonic acid—24% by weight; free sulfuric acid—29% by weight; and water—10% by weight. | 03-03-2016 |
20160068481 | Resveratrol selenide preparation for treating cancer - A trans-resveratrol selenide for treating cancer has such a structure as: | 03-10-2016 |
20160074347 | Processes For The Preparation Of 2,5-Dihydroxybenzenesulfonic Acid Salts - Processes for the preparation of 2,5-dihydroxybenzenesulfonic acid salts of formula (I) and a crystalline form of potassium 2,5-dihydroxybenzenesulfonic acid are provided. Also provided are methods of treating rosacea comprising administering crystalline forms of potassium 2,5-dihydroxybenzenesulfonic acid. | 03-17-2016 |
20160168077 | FORMS OF CO-CRYSTALS OF AGOMELATINE AND p TOLUENESULPHONIC ACID, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | 06-16-2016 |
514577000 | Polycyclo ring system | 7 |
20080234381 | Novel Trifluoromethoxy-Substituted Aryl Anilides - The present invention relates to novel compounds that act as chemical uncouplers. Compounds of the invention are useful in the treatment, including prevention, of obesity, diabetes and a number of diseases or disorders associated therewith. | 09-25-2008 |
20080293817 | ADMINISTRATION OF 6-[3-(1-ADAMANTYL)-4-METHOXYPHENYL]-2-NAPHTHOIC ACID FOR THE TREATMENT OF DERMATOLOGICAL DISORDERS - Dermatological disorders having an inflammatory or proliferative component are treated with pharmaceutical compositions containing on the order of 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefor, advantageously topically applicable gels, creams or lotions. | 11-27-2008 |
20090247639 | SULFONIC ACID AND ALDEHYDE CONDENSATION POLYMERS FOR THE TREATMENT AND PREVENTION OF HPV - The present invention relates to a method of treating and preventing a papillomavirus infection in an individual, comprising administering to the individual a therapeutically effective amount of a condensation polymer of an aromatic sulfonic acid and an aldehyde, or a pharmaceutically acceptable salt thereof. | 10-01-2009 |
20110034559 | Cell Repair And Regeneration By Suramin And Related Polysulfonated Naphthylureas - Disclosed herein are compositions and methods for promoting the repair and regeneration of injured tissues, such as injuries resulting from ischemic damage. Also disclosed are compositions and methods for accelerating wound healing in diabetic and elderly patients and inhibiting allograft failure. | 02-10-2011 |
20120190749 | STERILIZATION METHOD - It is an object of the present invention to provide a novel sterilization method capable of killing not only microorganisms in water, but also microorganisms in a gas. Specifically, the present invention provide a method for sterilizing a gas or liquid, comprising contacting a microorganism in a gas or liquid with a material containing an amorphous carbon having a sulfo group introduced therein. | 07-26-2012 |
20160159735 | COMPLEXES OF AGOMELATINE AND SULPHONIC ACIDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM - Complexes of agomelatine and sulphonic acids of formula (I): | 06-09-2016 |
20160250166 | METHOD FOR TREATING CHIKUNGUNYA VIRUS INFECTION | 09-01-2016 |